Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Risk in Survivors of Cancer

  • Cardio-Oncology (SA Francis, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Survivors of childhood and adult cancers face increased risk of cardiovascular disease. We review the current evidence base and guidelines for this rapidly growing population.

Recent Findings

Research continues to show that cardiovascular disease is an important cause of morbidity and mortality in cancer survivors. Cardiotoxicity related to chemotherapy and radiotherapy accounts for part of this increased risk. There is emerging evidence that cancer and cardiovascular disease share a similar biology and risk factors.

Summary

At present, there are several guidelines and consensus recommendations for the management of cardiovascular risk in cancer survivors. The evidence base is accumulating though additional research is necessary to demonstrate improved outcomes and comparative effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=445089. Accessed 4 Jan 2017.

  2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41. doi:10.3322/caac.21149.

    Article  PubMed  Google Scholar 

  3. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 15 Jan 2017.

  4. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 10 Jan 2017.

  5. •• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. Longo DL, ed. N Engl J Med. 2016;375(15):1457–1467. doi:10.1056/NEJMra1100265. This review provides a comprehensive overview of cardiovascular toxicity due to novel targeted cancer therapies.

  6. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. JACC JAC. 2009;53(24):2231–47. doi:10.1016/j.jacc.2009.02.050.

    Article  CAS  Google Scholar 

  7. Hahn VS, Lenihan DJ, Ky B. Cancer therapy–induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014;3(2):–e000665. doi:10.1161/JAHA.113.000665.

  8. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672–7. doi:10.1001/jama.1991.03470120074036.

    Article  CAS  PubMed  Google Scholar 

  9. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808–15. doi:10.1056/NEJM199103213241205.

    Article  CAS  PubMed  Google Scholar 

  10. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ. 2009;339(dec08 1):b4606. doi:10.1136/bmj.b4606.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; doi:10.1161/CIRCULATIONAHA.114.013777.

  12. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412–8.

    Article  CAS  PubMed  Google Scholar 

  13. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9.

    Article  PubMed  Google Scholar 

  14. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7.

    Article  CAS  PubMed  Google Scholar 

  15. •• Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013;26(9):1013–32. doi:10.1016/j.echo.2013.07.005. This expert consensus document provides a nice review of radiation-associated heart disease as well as practical guidelines for the practicing clinician.

    Article  PubMed  Google Scholar 

  16. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612–23. doi:10.1093/eurheartj/eht114.

    Article  PubMed  Google Scholar 

  17. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98. doi:10.1056/NEJMoa1209825.

    Article  CAS  PubMed  Google Scholar 

  18. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

    Article  CAS  PubMed  Google Scholar 

  20. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–65.

    Article  CAS  PubMed  Google Scholar 

  21. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12. doi:10.1016/j.jacc.2012.07.068.

    Article  CAS  PubMed  Google Scholar 

  22. Lenihan DJ, Oliva S, Chow EJ, Cardinale D. Cardiac toxicity in cancer survivors. Cancer. 2013;119(Suppl 11):2131–42.

    Article  PubMed  Google Scholar 

  23. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(Suppl 7):vii155–66.

    Article  Google Scholar 

  24. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.

    Article  PubMed  Google Scholar 

  25. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20.

    Article  CAS  PubMed  Google Scholar 

  26. Groarke JD, Nohria A. Anthracycline cardiotoxicity: a new paradigm for an old classic. Circulation. 2015;131(22):1946–9.

    Article  PubMed  Google Scholar 

  27. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):820–8.

    Article  CAS  Google Scholar 

  28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Survivorship Guidelines. Version 2. 2016.

  29. •• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2014;27(9):911–39. This expert consensus provides a nice review of chemotherapy-associated heart disease and provides practical guidelines for the practicing clinician particularly in regard to the role of cardiac imaging in the screening, diagnosis, and follow-up of patients with cardiotoxicity.

    Article  Google Scholar 

  30. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–14. doi:10.1161/CIRCULATIONAHA.115.020406.

    Article  PubMed  PubMed Central  Google Scholar 

  31. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(13):1429–37.

    Article  Google Scholar 

  32. Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25(Suppl 2):107–16.

    Article  PubMed  Google Scholar 

  33. Children’s Oncology Grop. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers Version 4.0. 2013.

  34. Sieswerda E, Postma A, van Dalen EC, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(8):2191–8.

    Article  CAS  Google Scholar 

  35. Wallace WH, Thompson L, Anderson RA, Guideline Development G. Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance. BMJ. 2013;346:f1190.

    Article  CAS  PubMed  Google Scholar 

  36. United Kingdon Children’s Cancer Study Late Effects Group. Therapy based long term follow up practice statement. 2005.

  37. Wong FL, Bhatia S, Landier W, et al. Cost-effectiveness of the children’s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med. 2014;160(10):672–83.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med. 2014;160(10):661–71.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013;60(4):543–9.

    Article  PubMed  Google Scholar 

  40. Steingart RM, Liu JE, Oeffinger KC. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. Ann Intern Med. 2014;160(10):731–2.

    Article  PubMed  Google Scholar 

  41. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.

    Article  PubMed  Google Scholar 

  42. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics. 2007;119(3):554–68.

    Article  PubMed  Google Scholar 

  43. Nathan PC, Hayes-Lattin B, Sisler JJ, Hudson MM. Critical issues in transition and survivorship for adolescents and young adults with cancers. Cancer. 2011;117(10 Suppl):2335–41.

    Article  PubMed  Google Scholar 

  44. Iyer NS, Mitchell HR, Zheng DJ, Ross WL, Kadan-Lottick NS. Experiences with the survivorship care plan in primary care providers of childhood cancer survivors: a mixed methods approach. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer. 2017 May;25(5):1547–55. doi:10.1007/s00520-016-3544-0. Epub 2017 Jan 3.

  45. Reppucci ML, Schleien CL, Fish JD. Looking for trouble: adherence to late-effects surveillance among childhood cancer survivors. Pediatr Blood Cancer. 2017;64(2):353–7.

    Article  PubMed  Google Scholar 

  46. Mertens AC, Cotter KL, Foster BM, et al. Improving health care for adult survivors of childhood cancer: recommendations from a delphi panel of health policy experts. Health policy (Amsterdam, Netherlands). 2004;69(2):169–78.

    Article  Google Scholar 

  47. Zebrack BJ, Eshelman DA, Hudson MM, et al. Health care for childhood cancer survivors: insights and perspectives from a Delphi panel of young adult survivors of childhood cancer. Cancer. 2004;100(4):843–50.

    Article  PubMed  Google Scholar 

  48. Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(27):4401–9.

    Article  Google Scholar 

  49. Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer. Circulation. 2016;133(5):537–41. doi:10.1161/CIRCULATIONAHA.115.012519.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tufts University School of Medicine, Boston, MA, USA

    Henry Chen Zheng

  2. Internal Medicine-Pediatrics Residency Program, Maine Medical Center, Portland, ME, USA

    Laura Onderko

  3. Cardiovascular Institute, Maine Medical Center, Portland, ME, USA

    Sanjeev A. Francis

Authors
  1. Henry Chen Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Onderko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanjeev A. Francis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjeev A. Francis.

Ethics declarations

Conflict of Interest

Henry Chen Zheng, Laura Onderko, and Sanjeev A. Francis declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardio-Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, H.C., Onderko, L. & Francis, S.A. Cardiovascular Risk in Survivors of Cancer. Curr Cardiol Rep 19, 64 (2017). https://doi.org/10.1007/s11886-017-0873-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0873-7

Keywords

Search

Navigation